Fatal e-cigarette or vaping associated lung injury (EVALI): a first case report in Europe

Camille Marlière1,7, Julien De Greef 1,2,7, Sophie Gohy3, Delphine Hoton4, Pierre Wallemacq2,5, Luc-Marie Jacquet6 and Leïla Belkhir1,2

Affiliations: 1Dept of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint Luc, Brussels, Belgium. 2Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de recherche expérimentale et clinique (IREC), UCLouvain, Brussels, Belgium. 3Pneumology Dept, Cliniques universitaires Saint Luc, Brussels, Belgium. 4Pathology Dept, Cliniques universitaires Saint Luc, Brussels, Belgium. 5Clinical Chemistry Dept, Cliniques universitaires St Luc, Brussels, Belgium. 6Cardiac ICU Dept, Cliniques universitaires Saint Luc, Brussels, Belgium. 7These authors have contributed equally to this work.

Correspondence: Julien De Greef, Dept of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium. E-mail: julien.degreef@uclouvain.be

Numerous cases of e-cigarette or vaping associated lung injury (EVALI) have been described, mainly in the US and Canada. However, public health and medical communities need to be aware that this deadly disease may occur outside North America.


To the Editor:

Numerous cases of e-cigarette, or vaping, associated lung injury (EVALI) have recently prompted an investigation of the outbreak in the USA [1]. Only two non-fatals cases have been reported so far in Europe: one case of hypersensitivity pneumonia in the UK after the use of flavoured e-cigarette liquid by a young adolescent [2], and one US imported case recently described in Spain [3]. To our knowledge, this is the first report of a fatal EVALI case in Europe.